3 SMALL CAPS Under $10 with Big Potential
3 extracted signals · 1 resolved · 2 still active
MarketBeatIndependent analyst profile- Source published
- 18 Jul 2026, 15:00 UTC
- Recorded by Tahlil Plus
- 18 Jul 2026, 15:53 UTC
AI-generated source summary
The analysis focuses on three small-cap stocks under $10, each identified with strong fundamentals and growth potential. The first stock, AVAN Health (AVAH), is a home healthcare provider with significant revenue from Medicare and Medicaid. It demonstrated 16% revenue growth last year and has increased its 2026 revenue guidance twice, indicating strong performance above management expectations. Its current price is $9.70, with a target price of $10.56 and a fail bound at $8.00, suggesting a bullish outlook. The second stock, GNW (Genworth Financial), is an insurance company with a $7 billion annual revenue and a P/E ratio of 17, below the S&P 500 average. Despite a complex history and a past decline due to long-term care policies, recent performance shows a clear upward trend over the last five years. It is considered profitable with 55% net profit margins in its PMI business. Its current price is $9.20, with a target of $15.25 and a fail bound at $7.00. The third stock, EGAN (eGain), is a micro-cap company with a $175 million market cap, founded in 1997. It is characterized as a resilient 'cockroach' company. The analysis suggests a potential for significant price movement, setting a target of $15.00 and a fail bound at $4.00, with a current price of $6.57. The company's customer relationship management software handling emails and databases is highlighted as an area where AI could improve efficiency. All three stocks are presented with a bullish outlook.
AI-generated summary based on the source content.
Signal outcomes at a glance
Partially ResolvedSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
3 eligible signals linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Live evaluation in progress
2 signals remain active.
MarketBeat
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.